Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lixte Biotechnology HoldingsLIXTW +4.74%34 EBIT per Share is $0.00 as of Jun. 2026. GuruFocus rates LIXTW with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 2,508 Industrial Products companies, Lixte Biotechnology Holdings ranks better than 85.01% on this metric.
Lixte Biotechnology Holdings's EBIT per Share for the
three
months ended in Jun. 2026 was $0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 35.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 22.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 4.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Lixte Biotechnology Holdings's EBIT per Share or its related term are showing as below:
LIXTW'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -55.2 Med: -1.1 Max: 35.8
Current: 35.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Lixte Biotechnology Holdings was 35.80% per year. The lowest was -55.20% per year. And the median was -1.10% per year.
LIXTW's 3-Year EBIT Growth Rate is ranked better than 85.01% of 2508
companies
in the Industrial Products industry
Industry Median: 4.8
vs LIXTW: 35.80
Lixte Biotechnology Holdings (NAS:LIXTW) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Lixte Biotechnology Holdings EBIT per Share Related Terms
Lixte Biotechnology Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lixte Biotechnology Holdings (LIXTW) has a EBIT per Share of $0.00 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lixte Biotechnology Holdings and its competitors. According to the industry distribution chart, Lixte Biotechnology Holdings ranks #376 out of 2508 companies in the Industrial Products industry, placing it in the top 15%.
Is Lixte Biotechnology Holdings' EBIT per Share too high?
Lixte Biotechnology Holdings' current EBIT per Share is $0.00. Based on the distribution chart, Lixte Biotechnology Holdings ranks #376 out of 2508 companies in the Industrial Products industry, which is in the top quartile — a strong position relative to peers. Overall, Lixte Biotechnology Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Lixte Biotechnology Holdings' EBIT per Share compare to CBAT and TGEN?
According to the Industrial Products industry distribution chart, Lixte Biotechnology Holdings ranks #376 out of 2508 companies for EBIT per Share. This places Lixte Biotechnology Holdings in the top 15% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 4.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for an Industrial Products company?
The median EBIT per Share among Industrial Products companies is 4.80, based on 2,508 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Lixte Biotechnology Holdings and its competitors. For the Industrial Products industry, the median EBIT per Share is 4.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lixte Biotechnology Holdings's current EBIT per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lixte Biotechnology Holdings stock overvalued right now?
Lixte Biotechnology Holdings (LIXTW) has a current EBIT per Share of $0.00. The current EBIT per Share is $0.00. Lixte Biotechnology Holdings' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Lixte Biotechnology Holdings (LIXTW), the current EBIT per Share is $0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
34GF Score
Get the complete analysis for LIXTW
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIXTW has been successfully added to your 
